

**8<sup>th</sup> International Workshop on Waldenström's Macroglobulinemia  
& Symposium on Advances in Multiple Myeloma (IWWM8)**

**Wednesday, August 13, 2014**

3:00-6:00 **Registration**

**Thursday, August 14, 2014**

<b>Session 1</b>	<b>Genetic Basis of WM I</b>		<b>Chair: Nikhil Munshi</b>
8:00	Zachary Hunter	USA	Genomic Landscape of WM
8:15	Marzia Varettoni	Italy	MYD88 L265P in IgM MGUS and WM
8:30	Xavier Leleu	France	MYD88 L265P in WM and related disorders
8:45	Bruno Paiva	Spain	Phenotypic and Genomic Evolution from MGUS to WM
9:00	<b>Discussion Session</b>		
9:30	<b>Coffee/Tea Break</b>		
<b>Session 2</b>	<b>Genetic Basis of WM II</b>		<b>Chair: Linda Pilarski</b>
10:00	Keisuke Horikawa	Australia	Consequences of MYD88 mutations in B cells
10:15	Alessandra Trojani	Italy	Gene expression profiling of WM and IGM MGUS
10:30	Stephanie Poulain	France	SNP array studies in WM
10:45	Steve Treon	USA	Clinical implications of MYD88 and CXCR4 mutations
11:00	Nikhil Munshi	USA	Comparative genomics of MM and WM
11:15	<b>Discussion Session</b>		
11:45	<b>Lunch Break</b>		
12:00-1:45	<b>Great Debates in Multiple Myeloma</b> <b>Chairs: Kenneth C. Anderson</b>  Should patients with high risk smoldering myeloma receive treatment? <b>Yes: Ola Landgren (USA)</b> <b>No: Morie Gertz (USA)</b>  Should triple therapy be the gold standard for frontline myeloma? <b>Yes: Nikhil Munshi (USA)</b> <b>No: Meletios Dimopoulos (Greece)</b>		Should autologous transplant be offered as consolidation to all eligible patients? <b>Yes: Bart Barlogie (USA)</b> <b>No: JP Feraud (France)</b>  Should pomalidomide or carfilzomib be the initial salvage treatment in myeloma? <b>Pomalidomide: Xavier Leleu (France)</b> <b>Carfilzomib: Philippe Moreau (France)</b>
<b>Session 3</b>	<b>Signaling in WM</b>		<b>Chair: Claudio Sette</b>
2:00	Claudio Sette	Italy	MYD88: Opportunities for Targeting WM
2:15	Guang Yang	USA	MYD88 Pathway Signaling in WM
2:30	Yang Cao	USA	CXCR4 Pathway Signaling in WM
2:45	Stephen Ansell	USA	IGM related signaling in WM
3:00	<b>Discussion Session</b>		
<b>Session 4</b>	<b>Origin of the WM Cell</b>		<b>Chair: Surinder Sahota</b>
3:30	Linda Pilarski	Canada	Origins of WM: Implications from Genetic Analysis

3:45	Ramón García Sanz	Spain	Does the immunophenotype of WM support a memory B-cell origin for WM?
4:00	Loizos Petrikkos	Greece	IgH Clonotypic sequence analysis and its support in WM
4:15	Surinder Sahota	UK	Phenotypic and genotypic evidence in tracing the cell of origin in WM.
4:30	<b>Discussion Session</b>		
5:00	<b>Day Highlights (Roger Owen, Workshop Co-Chair)</b>		
7:00-11:00	<b>Opening Ceremonies: Thames River Cruise/Dinner Reception (<i>Ticketed Event</i>) Special Guest Speaker: TBA Robert A. Kyle Award Ceremony</b>		
<b>Friday, August 15, 2014</b>			
<b>Session 5</b>	<b>Diagnosis of WM</b>		<b>Chair: Robert A. Kyle</b>
8:00	Roger Owen	UK	WM/LPL in the era of molecular diagnostics
8:15	Robert Kyle	USA	Where does IgM MGUS end and WM begin?
8:30	Lian Xu	USA	PB MYD88 testing for WM diagnosis
8:45	Ranjana Advani	USA	NCCN Diagnostic & Treatment Guidelines for WM
9:00	<b>Discussion Session</b>		
9:30	<b>Coffee/Tea Break</b>		
<b>Session 6</b>	<b>WM Predisposition</b>		<b>Chair: Mary McMaster</b>
10:00	Ola Landgren	USA	MGUS Predispositions
10:15	Mary McMaster	USA	Familial Studies in WM and IgM MGUS
10:30	H. Ögmundsdóttir	Iceland	Familial Studies in Iceland
10:45	Sigurdur Kristinsson	Iceland	Risk factors and outcome in WM/LPL
11:00	<b>Discussion Session</b>		
11:30	<b>Lunch Break</b>		
11:45-1:45	<b>Great Debates in Waldenstrom's Macroglobulinemia</b> Chairs: Veronique Leblond (France) and Shirley D'Sa (UK)		
	Should MYD88 and CXCR4 be tested in all WM patients? Yes: Xavier Leleu (France) No: Eva Kimby (Sweden)		Should carfilzomib be given instead of bortezomib for WM? Yes: Irene Ghobrial (USA) No: Meletios Dimopoulos (Greece)
	Should bendamustine or ibrutinib be the first salvage in WM? Bendamustine: Mathias Rummel (Germany) Ibrutinib: Lia Palomba (USA)		Are response criteria for WM adequate? Yes: Roger Owen (UK) No: Enrica Morra (Italy)
<b>Session 7</b>	<b>Novel Drug Development for WM</b>		<b>Chair: Steven T. Pals</b>
2:00	Xia Liu	USA	Direct Targeting in MYD88
2:15	Sara Buhrlage	USA	IRAK pathway inhibitors
2:30	Steven Pals	Netherlands	Targeting cell adhesion and migration in WM

2:45	Aldo Roccaro	USA	CXCR4 targeted therapy
3:00	<b>Discussion Session</b>		
<b>Session 8</b>	<b>Prognostication and Survival in WM</b>		<b>Chair: Ola Landgren</b>
3:30	Pierre Morel	France	Prognostication in the era of molecular markers
3:45	Stathis Kastritis	Greece	Competing risk factors for survival in WM
4:00	Jorge Castillo	USA	Improvements in WM survival by SEER
4:15	<b>Discussion Session</b>		
4:45	<b>Day Highlights (Shirley D'Sa, Workshop Co-Chair)</b>		
<b>Session 9</b> 4:00-7:00 5:00-7:00	<b>Poster Viewing Oral [13] &amp; Poster [36] Discussion Session of Invited Abstracts</b>		<b>Chairs: Roger Owen &amp; Charalampia Kyriakou</b>
<b>5:15-6:39</b>	<b>Oral Presentations</b>		
5:15	E.L. Smith	USA	<i>Poster W8; CD19 Targeted chimeric antigen modified T-cells for the treatment of WM</i>
5:22	V. Steingrimsson	Iceland	<i>Poster W26; Population based study on the impact of familial form of WM on overall survival</i>
5:29	A. Wechalekar	UK	<i>Poster W34; Characteristics and outcomes of IgM associated systemic AL amyloidosis-analysis of a prospective study [ALChem Study]</i>
5:36	J. Paludo	USA	<i>Poster W36; Clinical features and survival outcome of young patients with WM</i>
5:43	P. Milani	Italy	<i>Poster W21; Bendamustine is a well tolerated and effective rescue agent in AL amyloidosis, particularly in patients with WM</i>
5:50	I. Ghobrial	USA	<i>Poster W24; Clinical profile of single-agent modified-release oprozomib tablets in patients with WM: updated results from a multicenter, open-label, dose escalation, phase 1b/2 study</i>
5:57	J. Nielsen	Canada	<i>Poster W1; MYD88 L265P: A target for T cell based therapy of WM</i>
6:04	L. Simon	France	<i>Poster W6; Bing Neel Syndrome: the French experience</i>
6:11	W. Jiang	USA	<i>Poster W16; IMO-8400 inhibits MYD88 L265P mediated signaling and Cell growth in WM</i>
6:18	K. Argyropoulos	USA	<i>Poster W22; Multi-parameter single cell phospho-filing of the BCR signaling pathway in WM</i>
6:25	S. Guidez	France	<i>Poster W27; Prognostic importance of the quality of response to first line therapy in patients with WM</i>
6:32	M. Fulciniti	USA	<i>Poster W28; Critical growth and survival role of miR-23b/Sp1/NFkB pathway in WM</i>
6:39	D. Joshua	Australia	<i>Poster W31; Tumor induced immunosuppression in WM and MM. Marked differences in immune homeostatic balance between tumor and host</i>
<b>Saturday, August 16, 2014</b>			
<b>Session 10</b>	<b>Current Therapy of WM</b>		<b>Chair: Enrica Morra</b>
8:00	Véronique Leblond	France	Nucleoside Analogues
8:15	Christian Buske	Germany	Alkylator Based Therapy (Excluding Bendamustine)
8:30	Mathias Rummel	Germany	Bendamustine
8:45	M. Dimopoulos	Greece	Proteasome Inhibitors
9:00	Steven Treon	USA	Ibrutinib and other Signal Inhibitors
9:15	<b>Discussion Session</b>		
9:45	<b>Coffee/Tea Break</b>		
<b>Session 11</b>	<b>Treatment Considerations in WM</b>		<b>Chair: Meletios Dimopoulos</b>
10:15	Irene Ghobrial	USA	Integrating signal inhibitors into WM therapy

10:30	<b>Sandra Kanan</b>	USA	Rituximab intolerance and alternatives in WM
10:45	<b>Giampaolo Merlini</b>	Italy	Diagnosis and workup of the patient with amyloidosis
11:00	<b>Chara Kyriakou</b>	UK	Optimal timing for stem cell transplant in WM
11:15	<b>Enrica Morra</b>	Italy	Long term toxicity of therapy in WM
11:30	<b>Discussion Session</b>		
12:00	<b>Lunch</b>		
12:15-12:45	<b>Special Lecture: Shirley D'Sa (UK)</b>		<b>“Current Treatment Approaches to Waldenström’s macroglobulinemia in the United Kingdom”</b>
<b>Session 12</b>	<b>Special Topics in WM</b>		<b>Chair: Morie Gertz</b>
1:00	<b>Jean-Paul Fermand</b>	France	Etiologies and Interventions for renal failure in WM
1:15	<b>Marvin Stone</b>	USA	Cryoglobulinemia: When to suspect and how to manage in WM
1:30	<b>Sigbjorn Berentsen</b>	Norway	Cold Agglutinin disease and WM: Time for divorce?
1:45	<b>Michael Lunn</b>	UK	Diagnosis and Management of Peripheral Neuropathy in WM and IgM related disorders
2:00	<b>Monique Minnema</b>	Netherlands	Diagnostic and treatment challenges with Bing Neel Syndrome
2:15	<b>Evangelos Terpos</b>	Greece	Coagulopathies and acquired VW deficiency in WM
2:30	<b>Morie Gertz</b>	USA	ASCT in the WM patient with amyloidosis
2:45	<b>Discussion Session</b>		
3:15	<b>Day Highlights &amp; Conference Adjourn (Chara Kyriakou, Workshop Co-Chair)</b>		